Redfaces - SRX which you said you liked the other day has never partnered up with anyone, has not completed phase 3 trials, has borne the burden of a substantial seller for years, has battled multiple court cases, and whilst it extends lives it almost never cures patients completely of their cancer . Still it operates independently and profitibly .
I really don't think you can presume that PRR won't succeed just because it doesn't have a pharma partner yet . I find it very significant that an ex senior Pfizer employee is working with PRR and I don't think that should be discounted .
What are the options for Ovarian Cancer patients ?
figtree know the aussie market well, page-4
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.005(1.61%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 30.5¢ | $251.5K | 806.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 121215 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 2864 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |